Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Adapalene + Benzoyl Peroxide, Atc D10ad23 For The Period February 1st, 2026 - January 31st, 2028 (plus V. Option 1x12 Months) 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Pasireotide, Atc H01cb05 For The Period February 1, 2026 - January 31, 2028 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph 8 Sgb V For The Active Ingredient Brimonidine + Timolol, Atc S01ed69 For The Period February 1st, 2026 - January 31st, 2028 (plus Extension Option 1x12 Months) 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Betahistine, Atc N07ca01 For The Period 01.02.26 - 31.01.28 (plus Extension Option 1x12 Months) Betahistine 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Desvenlafaxin For The Period 01.02.2026 - 31.01.2028 (plus Extension Option 1x12 Months). Desvenlafaxin 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Progesterone For The Period 01.02.26 - 31.01.28 (plus Option For 1x12 Months). Progesterone 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Prednisolone, Atc S01ba04 For The Period 01.02.2026 - 31.01.2028 (plus Extension Option 1x12 Months). Prednisolone 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Brimonidine For The Period 01.02.26 - 31.01.28 (plus Option For 1x12 Months). Brimonidine 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Everolimus For The Period 01.02.2026 - 31.01.2028 (plus Extension Option 1x12 Months). Everolimus 2026-06-12
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Abs. 8 Sgb V For The Active Ingredient Teriparatide, Atc H05aa02 For The Period 01.02.2026 - 31.01.2027 (plus Extension Option 1x12 Months). Teriparatide 2026-06-12
Whats app